FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...

Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren ...

Biomarkers – including total levels of IgG and auto-antibodies – also improved and were consistent with nipocalimab’s mechanism of action. J&J is running a broad programme of clinical trials ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's disease (SjD), an autoimmune condition that affects millions of people ...

A Precise and Powerful Mechanism Nipocalimab is a fully human monoclonal antibody that works by selectively binding to the neonatal Fc receptor (FcRn), disrupting the recycling of IgG antibodies.

Nipocalimab’s mechanism involves blocking FcRn to reduce circulating immunoglobulin G (IgG) antibodies, which include autoantibodies associated with various autoimmune diseases. The FDA has ...

Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren’s ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson. The announcement comes 5 months after the ...

Johnson & Johnson’s nipocalimab is a fully human aglycosylated monoclonal antibody that targets the neonatal Fc receptor (FcRn). It is being developed for multiple autoimmune diseases ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies.